The discovery that dysregulation of the CDK4/6 pathway is involved in breast cancer (BC) cell proliferation [3] has led to the development of selective CDK4/6 inhibitors, which have dramatically changed the management of breast cancer (BC) patients in advanced settings [4]. This evidence concerns the gene CDK4 and breast cancer.